Literature DB >> 21864716

Arterial remodeling and atherosclerosis: miRNAs involvement.

Manuela Quintavalle1, Gianluigi Condorelli, Leonardo Elia.   

Abstract

Cardiometabolic diseases (CMD) (such as atherosclerosis, diabetes, and hypertension) are the primary cause of death and disability in the Western world. Although lifestyle programs and therapeutic approaches have significantly reduced the socio-economic burden of CMD, a large number of events still cannot be avoided (the so called residual risk). Recent developments in genetics and genomics provide a platform for investigating further this area with the aim of deepening our understanding of the atherosclerotic phenomena underlying CMD, for instance by providing better information on the type of subjects who would benefit the most from therapeutic interventions, or by discovering new genetic and metabolic derangements that may be targeted for the development of new interventions. MicroRNAs (miRNA) are short, non-coding RNAs that negatively regulate the expression of proteins by binding to specific sequences on the 3' region of target mRNAs. Bioinformatics analysis predicts that each miRNA may regulate hundreds of targets, suggesting that miRNAs may play roles in almost every biological pathway and process, including those of the cardiovascular system. Studies are beginning to unravel their fundamental importance in vessel biology. Here, we review recent advance regarding the involvement of miRNAs in arterial remodeling and atherosclerosis.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21864716     DOI: 10.1016/j.vph.2011.08.216

Source DB:  PubMed          Journal:  Vascul Pharmacol        ISSN: 1537-1891            Impact factor:   5.773


  18 in total

Review 1.  Epigenetics and vascular diseases.

Authors:  Matthew S Stratton; Floriana Maria Farina; Leonardo Elia
Journal:  J Mol Cell Cardiol       Date:  2019-06-15       Impact factor: 5.000

Review 2.  Non-coding RNAs in cerebral endothelial pathophysiology: emerging roles in stroke.

Authors:  Ke-Jie Yin; Milton Hamblin; Y Eugene Chen
Journal:  Neurochem Int       Date:  2014-04-03       Impact factor: 3.921

3.  MicroRNAs in Vascular Biology.

Authors:  Munekazu Yamakuchi
Journal:  Int J Vasc Med       Date:  2012-09-26

Review 4.  Epigenetics and Vascular Diseases: Influence of Non-coding RNAs and Their Clinical Implications.

Authors:  Leonardo Elia; Manuela Quintavalle
Journal:  Front Cardiovasc Med       Date:  2017-04-27

Review 5.  Non-coding RNAs and hypertension-unveiling unexpected mechanisms of hypertension by the dark matter of the genome.

Authors:  Kazuo Murakami
Journal:  Curr Hypertens Rev       Date:  2015

6.  Blood microRNAs in low or no risk ischemic stroke patients.

Authors:  Jun Rong Tan; Kay Sin Tan; Yu Xuan Koo; Fung Lin Yong; Chee Woon Wang; Arunmozhiarasi Armugam; Kandiah Jeyaseelan
Journal:  Int J Mol Sci       Date:  2013-01-22       Impact factor: 5.923

7.  From cellular senescence to age-associated diseases: the miRNA connection.

Authors:  Elisabeth Schraml; Johannes Grillari
Journal:  Longev Healthspan       Date:  2012-12-03

Review 8.  Lipid mediators in diabetic nephropathy.

Authors:  Swayam Prakash Srivastava; Sen Shi; Daisuke Koya; Keizo Kanasaki
Journal:  Fibrogenesis Tissue Repair       Date:  2014-09-03

9.  Galpha12 Protects Vascular Endothelial Cells from Serum Withdrawal-Induced Apoptosis through Regulation of miR-155.

Authors:  Hyeon Jeong Lee; Eun Jig Lee; MiRan Seo
Journal:  Yonsei Med J       Date:  2016-01       Impact factor: 2.759

10.  miR-26a inhibits atherosclerosis progression by targeting TRPC3.

Authors:  Min Feng; Daqian Xu; Lirui Wang
Journal:  Cell Biosci       Date:  2018-01-19       Impact factor: 7.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.